Beyond Air (XAIR)
Makes an ambient-air nitric oxide system for newborn respiratory care.
Something off on this page? Send us feedback.
Commercializes LungFit PH, a system that generates nitric oxide from ambient air for newborn respiratory care, through U.S. fixed-fee leases and international distributors. Revenue comes solely from this approved product while oncology and neurology programs remain investigational.
Generates nitric oxide from ambient air through the LungFit platform. LungFit PH, the only approved and revenue-producing product, is used with ventilatory support for term and near-term newborns with hypoxic respiratory failure associated with pulmonary hypertension. The system's plasma-pulse process and filter avoid the storage and delivery of high-pressure nitric-oxide cylinders.
Commercializes directly in the United States using fixed-fee leases that bundle consumables, maintenance, training, and backup support, while distributors serve markets elsewhere. Beyond Cancer develops ultra-high-concentration nitric oxide for solid tumors, and NeuroNOS develops selective inhibitors; both had no revenue and depend on funding. Revenue and commercialization remain tied to LungFit PH, regulatory clearance, reimbursement, distributors, third-party and sole-source suppliers, and the licensed generator technology.
Company facts
Categories
Target rangeAs of Sep 2, 2026
Latest analyst notes
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| Sep 1, 2026 | Lake Street | Initiate | Buy | $10 |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $15.2M · Total debt $23.6M · Total assets $32.9M · Shareholders' equity $2.0M
- Revenue
- $1.8M
- Operating income
- −$6.6M
- Net income
- −$7.9M
No dividends on record.
| Institutions29 holders · as of Mar 31, 2026 | 7.27% | 69.6K shares | |
| Insiders5 holders · as of Jul 31, 2026 | 22.94% | 219.7K shares | |
| Otherremainder | 69.79% | 668.4K shares |
957.6K company shares as of Sep 3, 2026 · institutions as of Mar 31, 2026 · holders as of their latest filing
Two share counts disagree (957.6K in the company's Sep 3, 2026 report, 720.5K elsewhere); stakes use the report.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Evidence |
|---|---|---|---|
Steven A. LisiInsiderdirector, officer: CEO and Chairman of the Board | 17.37% | 166,371 | Form 4filed Jul 23, 2025 ↗ |
Robert Scott GoodmanInsiderdirector, officer: Chief Executive Officer | 3.64% | 34,822 | Form 4filed Jul 31, 2026 ↗ |
Balyasny Asset Management L.P.Institution | 2.42% | 464,161 | 13Fas of Mar 31, 2026 |
Murchinson Ltd.Institution | 1.72% | 329,987 | 13Fas of Mar 31, 2026 |
Robert CareyInsiderdirector | 1.45% | 13,884 | Form 4filed Mar 17, 2025 ↗ |
| See all 25 → | |||
13F — a manager's quarterly holdings · Form 4 — an insider's transaction report
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Jul 29, 2026 | Daniel J. Moorhead | officer: Chief Financial Officer | +13,020 | $5.59 |
| Jul 29, 2026 | Robert Scott Goodman | director, officer: Chief Executive Officer | +104,166 | $5.59 |
